Welcome to the Johnson & Johnson Immunodermatology Newsroom! Below, please find the latest data, content, meeting news and leadership messages about our progress and commitment to developing transformational approaches and innovative medicines for diseases like psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS) and bullous pemphigoid (BP).

To read more about our progress and accomplishments in other disease areas, please visit our Gastroenterology, Maternal-Fetal, and Rheumatology newsrooms. Our Rheumatology Newsroom also includes our work in psoriatic arthritis (PsA), an immune-mediated rheumatologic disease that develops in up to 30 percent of people with PsO.1

Our Commitment to Immunodermatology

At Johnson & Johnson Innovative Medicine, we are steadfast in our commitment to address unmet need, uncover novel treatment approaches, and work collaboratively to deliver transformational therapies for patients living with chronic immune-mediated diseases. We understand that significant unmet need remains in many of these diseases, and that patients around the world are struggling to find safe, effective treatments, and maintain symptom-free remission.

Building upon our portfolio of transformational advanced therapies which will continue to offer important treatment options for patients with immune-mediated diseases, we believe the pursuit of novel oral therapies is critical to reaching the many people still not receiving advanced therapies and ensuring patients have more options that offer the potential for remission. Driven by a relentless commitment to patients, we continue to pioneer research to achieve our vision of restoring health for all patients with immune-mediated diseases.